Filtered By:
Drug: Diovan

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 78 results found since Jan 2013.

The initial timing and dosage pattern of sacubitril/valsartan in patients with acute myocardial infarction undergoing percutaneous coronary intervention
CONCLUSIONS: Early use or high dosage of sacubitril/valsartan medication is associated with an improvement in clinical outcome. The low dose of sacubitril/valsartan is well tolerated and may be an acceptable alternative strategy.PMID:36990878 | DOI:10.1016/j.ejim.2023.03.019
Source: European Journal of Internal Medicine - March 29, 2023 Category: Internal Medicine Authors: Jun Gu Yue Wang Chang-Qian Wang Jun-Feng Zhang Source Type: research

Brain-targeted delivery of Valsartan using solid lipid nanoparticles labeled with Rhodamine B; a promising technique for mitigating the negative effects of stroke
Drug Deliv. 2023 Dec;30(1):2179127. doi: 10.1080/10717544.2023.2179127.ABSTRACTThe brain is a vital organ that is protected from the general circulation and is distinguished by the presence of a relatively impermeable blood brain barrier (BBB). Blood brain barrier prevents the entry of foreign molecules. The current research aims to transport valsartan (Val) across BBB utilizing solid lipid nanoparticles (SLNs) approach to mitigate the adverse effects of stroke. Using a 32-factorial design, we could investigate and optimize the effect of several variables in order to improve brain permeability of valsartan in a target-spec...
Source: Drug Delivery - February 16, 2023 Category: Drugs & Pharmacology Authors: Shereen A Sabry Amal M Abd El Razek Mohamed Nabil Shaimaa M Khedr Hanan M El-Nahas Noura G Eissa Source Type: research

Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control Hypertension
RARITAN, NJ, November 7, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Idorsia Ltd, today announced results from the Phase 3 PRECISION study, which found aprocitentan, an investigational, novel dual endothelin receptor antagonist (ERA), significantly reduced blood pressure (BP) and maintained the effect for up to 48 weeks when added to standardized combination background antihypertensive therapy in patients with difficult-to-control hypertension (sometimes referred to as resistant hypertension). These data were presented as a Late-Breaking Science presentation during the Amer...
Source: Johnson and Johnson - November 7, 2022 Category: Pharmaceuticals Source Type: news

Haemodynamic Effects of Sacubitril/Valsartan Initiation in Outpatients with Chronic Heart Failure
ConclusionThe vasodilative effects of S/V result in immediate reductions in SVRI, SBP, SV and CI. However, S/V induces reverse cardiac remodelling, which is apparent shortly after treatment initiation and leads to improvements of clinical, functional, echocardiographic, laboratory and haemodynamic variables.
Source: American Journal of Cardiovascular Drugs - September 22, 2022 Category: Cardiology Source Type: research

Cost Effectiveness of the First ‐in‐Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting
ConclusionsThis was the first study to evaluate the cost effectiveness of sacubitril/valsartan in the treatment of hypertension. Sacubitril/valsartan compares favorably with allisartan isoproxil and valsartan in the Chinese setting, which is mainly due to its higher efficacy resulting in fewer cardiovascular events and ultimately less related mortality over time. The results could inform deliberations regarding reimbursement and access to this treatment in China and may provide reference for facilitating more reasonable and efficient allocation of limited resources in such low- and middle-income countries.
Source: PharmacoEconomics - September 8, 2022 Category: Health Management Source Type: research

Left ventricular output indices and sacubitril/valsartan titration: role of stroke volume index
ConclusionsStroke volume index is positively associated with complete titration of sacubitril/valsartan. Patients with low SVi are more prone to experience hypotension during titration
Source: ESC Heart Failure - March 23, 2022 Category: Cardiology Authors: Paolo Tolomeo, Ottavio Zucchetti, Emanuele D'Aniello, Noemi Punzo, Federico Marchini, Luca Di Ienno, Elisabetta Tonet, Rita Pavasini, Claudio Rapezzi, Gianluca Campo, Matteo Serenelli Tags: Short Communication Source Type: research

Cardiopulmonary exercise test-based assessment of the effects of sacubitril/valsartan on the blood pressure response to exercise in patients with acute myocardial infarction during hospitalization
CONCLUSION: Treatment with S/V was able to reduce the exercise blood pressure in patients with AMI during hospitalization, but did not significantly improve the VO2 peak, VE/VCO2 slope, or exercise tolerance.PMID:35315303 | DOI:10.1080/10641963.2022.2055765
Source: Clinical and Experimental Hypertension - March 22, 2022 Category: Cardiology Authors: Chun-Mei Zeng Yan-Mei Zhao Yi-Yi Li Zhi-Hai Lin Ping Li Ying Feng Jian-Ping Tan Kai-Fang Pang Source Type: research

IJERPH, Vol. 19, Pages 2089: ARNI in HFrEF & mdash;One-Centre Experience in the Era before the 2021 ESC HF Recommendations
Conclusions: Our current positive experience in ARNI therapy is limited to extremely severe patients with HFrEF. Regardless of the more advanced HF and HF comorbidities, the patients treated with ARNI presented similar mortality and rehospitalizations as the patients treated by standard therapy.
Source: International Journal of Environmental Research and Public Health - February 13, 2022 Category: Environmental Health Authors: Rafa ł Niemiec Irmina Morawska Maria Stec Wiktoria Kuczmik Andrzej S. Swinarew Arkadiusz Stanula Katarzyna Mizia-Stec Tags: Article Source Type: research